

CCT241736

## Chemical Properties


CAS No. : 1402709-93-6

Formula: C<sub>22</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>7</sub>

Molecular Weight: 456.37

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3, CCT241736, an advanced analog of CCT137690, is a preclinical development candidate for the treatment of human malignancies, and in particular AML in adults and children.
Targets(IC50)	FLT,Aurora Kinase
In vivo	UNC2025 was capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow.

## Solubility Information

Solubility	DMSO: 75 mg/mL (164.34 mM),Sonication is recommended. H <sub>2</sub> O: < 0.1 mg/mL (insoluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 3.3 mg/mL (7.23 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.1912 mL	10.956 mL	21.912 mL
5 mM	0.4382 mL	2.1912 mL	4.3824 mL
10 mM	0.2191 mL	1.0956 mL	2.1912 mL
50 mM	0.0438 mL	0.2191 mL	0.4382 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Bavetsias V,etal. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.J Med Chem. 2012 Oct 25;55(20):8721-34.

Bavetsias V,etal.Aurora Kinase Inhibitors: Current Status and Outlook.Front Oncol. 2015 Dec 21;5:278.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481